Intravenous magnetic nanoparticle cancer hyperthermia

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2521-2532

  Huang, Hui S ^a   Hainfeld, James F ^a  

^a Nanoprobes   (United States)

Author keywords

Alternating magnetic field; Cancer; Hyperthermia; Intravenous delivery; Magnetic nanoparticles

Indexed keywords

MAGNETIC NANOPARTICLE; MAGNETITE NANOPARTICLE;

ALTERNATING MAGNETIC FIELD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; FEMALE; HYPERTHERMIC THERAPY; INDUCTION HEATER; MAGNETIC FIELD; MEDICAL DEVICE; MOUSE; NONHUMAN; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS TISSUE TUMOR; TUMOR ABLATION;

ALTERNATING MAGNETIC FIELD; CANCER; HYPERTHERMIA; INTRAVENOUS DELIVERY; MAGNETIC NANOPARTICLES;

ADMINISTRATION, INTRAVENOUS; ANIMALS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HYPERTHERMIA, INDUCED; IRON; MAGNETITE NANOPARTICLES; MICE; NEOPLASMS; THERMOGRAPHY; TISSUE DISTRIBUTION;

EID: 84880446225     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S43770     Document Type: Article

References (94)

1. Hergt R, Dutz S, Röder M. Effects of size distribution on hysteresis losses of magnetic nanoparticles for hyperthermia. J Phys Condens Matter. 2008;20(38):385214.
2. Rosensweig RE. Heating magnetic fluid with alternating magnetic field. J Magn Magn Mater. 2002;252(1-3):370-374.
3. Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parrott JC, Taylor CB. Selective inductive heating of lymph nodes. Annals of surgery. 1957;146(4):596-606.
4. Chan DC, Kirpotin DB, Bunn PA Jr. Synthesis and evaluation of colloidal magnetic iron oxides for the site-specific radiofrequency-induced hyperthermia of cancer. J Magn Magn Mater. 1993;122(1-3):374-378.
5. Jordan A, Wust P, Fahling H, John W, Hinz A, Felix R. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia. 1993;9(1):51-68.
6. Rand RW, Snow HD, Brown WJ. Thermomagnetic surgery for renal cancer. Prog Clin Biol Res. 1982;100:673-685.
7. Kumar CS, Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv Drug Deliv Rev. 2011;63(9):789-808.
8. Laurent S, Dutz S, Häfeli UO, Mahmoudi M. Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. Adv Colloid Interface Sci. 2011;166(1-2):8-23.
9. Berry CC. Progress in functionalization of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys. 2009;42(22).
10. Pankhurst QA, Thanh NT, Jones SK, Dobson J. Progress in applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys. 2009;42(22).
11. Roca AG, Costo R, Rebolledo AF, et al. Progress in the preparation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys. 2009;42(22).
12. Kobayashi T. Cancer hyperthermia using magnetic nanoparticles. Biotechnology journal. 2011;6(11):1342-1347.
13. Amstad E, Reimhult E. Nanoparticle actuated hollow drug delivery vehicles. Nanomedicine (Lond). 2012;7(1):145-164.
14. Edelman ER, Brown L, Kost J, Taylor J, Langer R. Modulated release from polymeric drug delivery systems using oscillating magnetic fields: in vitro and in vivo characteristics. Transactions - American Society for Artificial Internal Organs. 1984;30:445-449.
15. Kost J, Noecker R, Kunica E, Langer R. Magnetically controlled release systems: effect of polymer composition. Journal of biomedical materials research. 1985;19(8):935-940.
16. Kost J, Wolfrum J, Langer R. Magnetically enhanced insulin release in diabetic rats. Journal of biomedical materials research. 1987;21(12):1367-1373.
17. Su W, Wang H, Wang S, et al. PEG/RGD-modified magnetic polymeric liposomes for controlled drug release and tumor cell targeting. International journal of pharmaceutics. 15 2012;426(1-2):170-181.
18. Hosokawa T, Sami M, Kato Y, Hayakawa E. Alteration in the temperature-dependent content release property of thermosensitive liposomes in plasma. Chemical & pharmaceutical bulletin. 2003;51(11):1227-1232.
19. Masuko Y, Tazawa K, Viroonchatapan E, et al. Possibility of thermosensitive magnetoliposomes as a new agent for electromagnetic induced hyperthermia. Biol Pharm Bull. 1995;18(12):1802-1804.
20. Viroonchatapan E, Sato H, Ueno M, et al. Microdialysis assessment of 5-fluorouracil release from thermosensitive magnetoliposomes induced by an electromagnetic field in tumor-bearing mice. J Drug Target. 1998;5(5):379-390.
21. Peiris PM, Bauer L, Toy R, et al. Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug release. ACS nano. 2012;6(5):4157-4168.
22. Babincov M, Altanerov V, Altaner C, Bergemann C, Babinec P. In vitro analysis of cisplatin functionalized magnetic nanoparticles in combined cancer chemotherapy and electromagnetic hyperthermia. IEEE Trans Nanobioscience. 2008;7(1):15-19.
23. Zhang J, Misra RD. Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: core-shell nanoparticle carrier and drug release response. Acta Biomater. 2007;3(6):838-850.
24. Hu SH, Liao BJ, Chiang CS, Chen PJ, Chen IW, Chen SY. Core-shell nanocapsules stabilized by single-component polymer and nanoparticles for magneto-chemotherapy/hyperthermia with multiple drugs. Adv Mater. 2012;24(27):3627-3632.
25. Ren Y, Zhang H, Chen B, et al. Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. International Journal of Nanomedicine. 2012;7:2261-2269.
26. Le Renard PE, Jordan O, Faes A, et al. The in vivo performance of magnetic particle-loaded injectable, in situ gelling, carriers for the delivery of local hyperthermia. Biomaterials. 2010;31(4):691-705.
27. Park J, An K, Hwang Y, et al. Ultra-large-scale syntheses of monodisperse nanocrystals. Nat Mater. 2004;3(12):891-895.
28. Fortin JP, Wilhelm C, Servais J, Ménager C, Bacri JC, Gazeau F. Size-sorted anionic iron oxide nanomagnets as colloidal mediators for magnetic hyperthermia. J Am Chem Soc. 2007;129(9):2628-2635.
29. Lee JH, Jang JT, Choi JS, et al. Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nanotechnol. 2011;6(7):418-422.
30. Lacava LM, Lacava ZGM, Azevedo RB, et al. Use of magnetic resonance to study biodistribution of dextran-coated magnetic fluid intravenously administered in mice. J Magn Magn Mater. 2002;252(1-3).
31. White DL, Aicher KP, Tzika AA, Kucharczyk J, Engelstad BL, Moseley ME. Iron-dextran as a magnetic susceptibility contrast agent: flow-related contrast effects in the T2-weighted spin-echo MRI of normal rat and cat brain. Magn Reson Med. 1992;24(1):14-28.
32. Kohler N, Sun C, Fichtenholtz A, Gunn J, Fang C, Zhang M. Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small. 2006;2(6):785-792.
33. Xie J, Xu C, Xu Z, et al. Linking Hydrophilic Macromolecules to Monodisperse Magnetite (Fe(3)O(4)) Nanoparticles via Trichloro-s-triazine. Chem Mater. 2006;18(23):5401-5403.
34. Jordan A, Scholz R, Wust P, et al. Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro. J Magn Magn Mater. 1999;194(1-3):185-196.
35. Carpenter EE. Iron nanoparticles as potential magnetic carriers. J Magn Magn Mater. 2001;225(1-2):17-20.
36. Park HY, Schadt MJ, Wang L, et al. Fabrication of magnetic core@shell Fe oxide@Au nanoparticles for interfacial bioactivity and bio-separation. Langmuir. 2007;23(17):9050-9056.
37. Miller KJ, Colletti A, Papi PJ, McHenry ME. Fe-Co-Cr nanocomposites for application in self-regulated rf heating. J Appl Phys. 2010; 107(9).
38. Shido Y, Nishida Y, Suzuki Y, Kobayashi T, Ishiguro N. Targeted hyperthermia using magnetite cationic liposomes and an alternating magnetic field in a mouse osteosarcoma model. J Bone Joint Surg Br 2010;92(4):580-585.
39. Pop M, Cosma-Cachita D, Bica D, Tarca A, Tripşa M. Magnetoliposomes obtained from lecithin and Fe3O4 nanoparticles. Rom J Physiol. 1999;36(3-4):233-236.
40. Skouras A, Mourtas S, Markoutsa E, et al. Magnetoliposomes with high USPIO entrapping efficiency, stability and magnetic properties. Nanomedicine. 2011;7(5):572-579.
41. Hilger I, Hergt R, Kaiser WA. Use of magnetic nanoparticle heating in the treatment of breast cancer. IEE Proc Nanobiotechnol. 2005;152(1): 33-39.
42. Ito A, Tanaka K, Honda H, Abe S, Yamaguchi H, Kobayashi T. Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. J Biosci Bioeng. 2003;96(4):364-369.
43. Matsuoka F, Shinkai M, Honda H, Kubo T, Sugita T, Kobayashi T. Hyperthermia using magnetite cationic liposomes for hamster osteosarcoma. Biomagn Res Technol. 2004;2(1):3.
44. Motoyama J, Yamashita N, Morino T, Tanaka M, Kobayashi T, Honda H. Hyperthermic treatment of DMBA-induced rat mammary cancer using magnetic nanoparticles. Biomagn Res Technol. 2008;6:2.
45. Dennis CL, Jackson AJ, Borchers JA, et al. Nearly complete regression of tumors via collective behavior of magnetic nanoparticles in hyperthermia. Nanotechnology. 2009;20(39):395103.
46. Tanaka K, Ito A, Kobayashi T, et al. Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma. J Biosci Bioeng. 2005;100(1):112-115.
47. Zhai Y, Xie H, Gu H. Effects of hyperthermia with dextran magnetic fluid on the growth of grafted H22 tumor in mice. Int J Hyperthermia. 2009;25(1):65-71.
48. Basel MT, Balivada S, Wang H, et al. Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased survival in a murine pancreatic cancer model. International journal of nanomedicine. 2012;7:297-306.
49. Suzuki M, Shinkai M, Honda H, Kobayashi T. Anticancer effect and immune induction by hyperthermia of malignant melanoma using magnetite cationic liposomes. Melanoma research. 2003;13(2):129-135.
50. Johannsen M, Gneveckow U, Eckelt L, et al. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperthermia. 2005;21(7):637-647.
51. Maier-Hauff K, Rothe R, Scholz R, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol. 2007;81(1):53-60.
52. van Landeghem FK, Maier-Hauff K, Jordan A, et al. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials. 2009;30(1):52-57.
53. Hainfeld JF, O'Connor MJ, Dilmanian FA, Slatkin DN, Adams DJ, Smilowitz HM. Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions. Br J Radiol. 2011;84(1002):526-533.
54. Hainfeld JF, Smilowitz HM, O'Connor MJ, Dilmanian FA, Slatkin DN. Gold nanoparticle imaging and radiotherapy of brain tumors in mice. Nanomedicine (Lond). Epub December 24, 2012.
55. Dutz S, Kettering M, Hilger I, Muller R, Zeisberger M. Magnetic particle hyperthermia - Properties of magnetic multicore nanoparticles administered to tumor tissue. Biomedizinische Technik. Biomedical engineering. 2012:76.
56. Hilger I, Hiergeist R, Hergt R, Winnefeld K, Schubert H, Kaiser WA. Thermal ablation of tumors using magnetic nanoparticles: an in vivo feasibility study. Invest Radiol. 2002;37(10):580-586.
57. Balivada S, Rachakatla RS, Wang H, et al. A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study. BMC Cancer. 2010;10:119.
58. DeNardo SJ, DeNardo GL, Natarajan A, et al. Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF - induced thermoablative therapy for human breast cancer in mice. J Nucl Med. 2007;48(3):437-444.
59. Shinkai M, Le B, Honda H, et al. Targeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomes. Jpn J Cancer Res. 2001;92(10):1138-1145.
60. Hergt R, Dutz S. Magnetic particle hyperthermia - biophysical limitations of a visionary tumour therapy. J Magn Magn Mater. 2007;311(1): 187-192.
61. Samanta B, Yan H, Fischer NO, Shi J, Jerry DJ, Rotello VM. Protein-passivated Fe(3)O(4) nanoparticles: low toxicity and rapid heating for thermal therapy. J Mater Chem. 2008;18(11):1204-1208.
62. 3 nanoparticles. J Phys Condens Matter. 2008;20(20):204133.
63. Mornet S, Vasseur S, Grasset F, Duguet E. Magnetic nanoparticle design for medical diagnosis and therapy. J Mater Chem. 2004;14(14): 2161-2175.
64. Ceriotti F, Ceriotti G. Improved direct specific determination of serum iron and total iron-binding capacity. Clin Chem. 1980;26(2):327-331.
65. Yang T, Shen C, Li Z, et al. Highly ordered self-assembly with large area of Fe3O4 nanoparticles and the magnetic properties. J Phys Chem B. 2005;109(49):23233-23236.
66. Reardon TF, Allen DG. Iron injections in mice increase skeletal muscle iron content, induce oxidative stress and reduce exercise performance. Exp Physiol. 2009;94(6):720-730.
67. Moroz P, Jones SK, Gray BN. Tumor response to arterial embolization hyperthermia and direct injection hyperthermia in a rabbit liver tumor model. J Surg Oncol. 2002;80(3):149-156.
68. Nomura T, Shibahara T, Katakura A, Matsubara S, Takano N. Establishment of a murine model of bone invasion by oral squamous cell carcinoma. Oral Oncol. 2007;43(3):257-262.
69. Glöckl G, Hergt R, Zeisberger M, Dutz S, Nagel S, Weitschies W. The effect of field parameters, nanoparticle properties and immobilization on the specific heating power in magnetic particle hyperthermia. J Phys Condens Matter. 2006;18(38):S2935.
70. Larsen EK, Nielsen T, Wittenborn T, et al. Accumulation of magnetic iron oxide nanoparticles coated with variably sized polyethylene glycol in murine tumors. Nanoscale. 2012;4(7):2352-2361.
71. Chen B, Zuberi M, Borgens RB, Cho Y. Affinity for, and localization of, PEG-functionalized silica nanoparticles to sites of damage in an ex vivo spinal cord injury model. Journal of biological engineering. 2012;6(1):18.
72. Hilger I, Andrä W, Hergt R, Hiergeist R, Schubert H, Kaiser WA. Electromagnetic heating of breast tumors in interventional radiology: in vitro and in vivo studies in human cadavers and mice. Radiology. 2001;218(2):570-575.
73. Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst. 1992;9(2):135-187.
74. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71-79.
75. Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev. 2011;63(8): 623-639.
76. Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103(2):317-324.
77. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005;352(10):987-996.
78. Hainfeld JF, Dilmanian FA, Zhong Z, Slatkin DN, Kalef-Ezra JA, Smilowitz HM. Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinoma. Phys Med Biol. 2010;55(11): 3045-3059.
79. Dutz S, Kettering M, Hilger I, Müller R, Zeisberger M. Magnetic multicore nanoparticles for hyperthermia - influence of particle immobilization in tumour tissue on magnetic properties. Nanotechnology. 2011;22(26):265102.
80. Lewis R. Sax's Dangerous Properties of Industrial Materials. Vol 1-3. 9 ed. New York: Van Nostrand Reinhold; 1996:2722.
81. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659-661.
82. Pfizer. Cisplatin injection [product information]. New York, NY: Pfizer; nd [updated Apr 2012]. Available from: http://www.pfizer.com/files/products/uspi_cisplatin.pdf. Accessed January 5, 2013.
83. Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg. 1984;119(6):647-651.
84. Noguchi Y, Wu J, Duncan R, et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res. 1998;89(3):307-314.
85. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol. 1988;133(1):95-109
86. Yao L, Danniels J, Moshnikova A, et al. pHLIP peptide targets nanogold particles to tumors. Proc Natl Acad Sci U S A. 2013;110(2):465-470.
87. Ivkov R, DeNardo SJ, Daum W, et al. Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer. Clin Cancer Res. 2005;11(19 Pt 2):7093s-7103s.
88. Liangruksa M, Ganguly R, Puri IK. Parametric investigation of heating due to magnetic fluid hyperthermia in a tumor with blood perfusion. J Magn Magn Mater. 2011;323(6):708-716.
89. Hergt R, Andra W, d'Ambly CG, et al. Physical limits of hyperthermia using magnetite fine particles. IEEE Trans Magn. 1998;34(5): 3745-3754.
90. Wiekhorst F, Steinhoff U, Eberbeck D, Trahms L. Magnetorelaxometry assisting biomedical applications of magnetic nanoparticles. Pharm Res. 2012;29(5):1189-1202.
91. Yuan Y, Wyatt C, Maccarini P, et al. A heterogeneous human tissue mimicking phantom for RF heating and MRI thermal monitoring verification. Phys Med Biol. 2012;57(7):2021-2037.
92. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002;43(1):33-56.
93. Rao W, Deng ZS, Liu J. A review of hyperthermia combined with radiotherapy/chemotherapy on malignant tumors. Crit Rev Biomed Eng. 2010;38(1):101-116.
94. Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3(8):487-497.